ClosedLoop Health is now VizLoop.
Our new name reflects the workflow we’re building for pharma teams: Observe → Compare → Act → Re-measure.
Methodology, findings, and label-change analysis from the team measuring what AI engines tell patients and clinicians about prescription medicines.
Our new name reflects the workflow we’re building for pharma teams: Observe → Compare → Act → Re-measure.
Every material AI engine change passes through someone's review process before it ships: the vendor's. What never happens is review by the people whose regulated products the changed answers describe.
Two documents about AI answers and prescription drugs circulated in June 2026, and the distance between them is the clearest picture available of where this field actually is.
June 2026 was a regulator's month. The substantive, verifiable movement came from Denver and Brussels, not from the AI engines.
If your compliance calendar for AI in healthcare was written before June 2026, at least three of its dates are now wrong. None of the changes made the substantive obligations lighter. All of them changed when, and in one case whether, those obligations arrive.
One framing correction before anything else, because precision is the point of this blog: OpenEvidence was not kicked out of Europe. No regulator ordered it off the market, no enforcement action names it, and no ban exists.
Every captured answer is checked against the safety elements the current label requires. The unit of measurement is the omission, and the denominator is always the label version in force on the day of capture.
Email subscriptions are paused. All posts remain available on the blog.